Stem Cell Therapy

Drugs in development to treat moderate to severe subacute and chronic atopic dermatitis

   ADSTEM Inj. Overview

Our company is currently developing treatments for moderate to severe subacute and chronic atopic dermatitis, with Phase 1 clinical trials underway at Chungnam National University Hospital.

We are continuing research and development to obtain approval for adult stem cell therapy products through Phase 2 and Phase 3 clinical trials.

   Indications

Our ADSTEM Inj. targets moderate to subacute and chronic atopic dermatitis.

   Usage Volume

Low Dose  1.0 x 108 cell / 10 ml / syringe

High Dose  3.0 x 108 cell / 10 ml / 3 syringes

One-time intravenous administration of autologous adipose-derived stem cells

Translate »